At week 26, more participants in the semaglutide groups (semaglutide 3 mg, 7 mg, and 14 mg) respectively than in the placebo group achieved weight reductions of 3% (18.0%, 36.9%, 50.6% vs
Novo Nordisk previously claimed to have been alarmed by "reports of medical spas, weight loss clinics, pharmacies, and other companies" selling compounded semaglutide to patients on the grounds that they "do not have the same safety, quality, and effectiveness assurances as Novo Nordisk's FDA-approved drugs." Compounding pharmacies are mostly regulated at the state level by boards of pharmacy
CYP2A6 is primarily expressed in the liver, where it constitutes 4% of total CYP expression (28)
However, this is expected, as the Italian Medicines Agency recently passed a decision to allow practitioners, as opposed to specialists only, in Italy to prescribe GLP-1 RAs to metformin-receiving patients [24]